Patents by Inventor Sang-Dug Han

Sang-Dug Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10278928
    Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: May 7, 2019
    Assignee: Dong-A Pharmaceutical Co., Ltd
    Inventors: Soon Hoe Kim, Mi Won Son, Sun Woo Jang, Joon Ho Jun, Sang Dug Han, Sung Rak Choi, Dae Hwan Kim, Yong Sung Sohn, Yong Sam Kwon
  • Publication number: 20150374641
    Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.
    Type: Application
    Filed: February 11, 2014
    Publication date: December 31, 2015
    Inventors: Soon Hoe KIM, Mi Won SON, Sun Woo JANG, Joon Ho JUN, Sang Dug HAN, Sung Rak CHOI, Dae Hwan KIM, Yong Sung SOHN, Yong Sam KWON
  • Publication number: 20130039951
    Abstract: Provided is a process for preparing a solubilized and stabilized formulation of a sirolimus derivative, which comprises the steps of a dissolving a sirolimus derivative in a solvent, and bring a solution of the sirolimus derivative into contact with a water-soluble carrier to disperse the sirolimus derivative in the water-soluble carrier, and a formulation of a sirolimus derivative with improved solubility and stability as prepared by the preparation process as above.
    Type: Application
    Filed: September 30, 2011
    Publication date: February 14, 2013
    Applicant: DONG-A PHARM. CO., LTD.
    Inventors: Soon-Hoe Kim, Mi-Won Son, Sun-Woo Jang, Sang-Kuk Park, Sang-Dug Han, Myung-Joo Kang, Kyung-Wan Ma
  • Publication number: 20110250279
    Abstract: This invention relates to a controlled-release composition for producing a sustained-release preparation containing udenafil, including (A) udenafil and a pharmaceutically acceptable salt, (B) a solubility modulator, (C) an adsorbent, and (D) a hydrophilic polymer. This controlled-release composition for producing a sustained-release preparation containing udenafil releases drugs constantly regardless of the pH level in the gastrointestinal tract, and thus freely controls the drug release time within the range of 3˜24 hours, and reduces the variability in the effect of drugs among individuals. Also, this composition can be produced into a sustained-release preparation which has an optimum condition for expressing the effect of drugs in the treatment of diseases including pulmonary arterial hypertension, hepatic portal vein hypertension, benign prostatic hyperplasia, and the like, which can be treated by udenafil and which requires the long-term drug administration.
    Type: Application
    Filed: December 10, 2009
    Publication date: October 13, 2011
    Applicant: Dong-A Pharm. Co., Ltd.
    Inventors: Moo-Hi Yoo, Bong-Jin Cha, Jeong-Hoon Kim, Sun-Woo Jang, Sang-Dug Han